Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
|Articles|March 19, 2016
Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL
Author(s)Silas Inman
A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.
Advertisement
Susan M. O’Brien, MD
With the onslaught of new PI3K and BTK inhibitors currently in development for patients with relapsed chronic lymphocytic leukemia (CLL), it is challenging to know which therapies are truly “next-generationâ€
Advertisement
Related to this article
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
Long-Term and Novel ADC Data Dominate Top Gynecologic Cancer Abstracts at ESMO 2026
3
FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
4
SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma
5